Insider trade

Officer sold ~$3.95M of JNJ shares in the open market

Traded Aug 17, 2026 · Filed Aug 18, 2026

Johnson & JohnsonJNJ

~$3.95M
Reported value · 15K sh @ $263.36: 194K
Holds after · shares reported: -1.4%
stock since the trade · S&P 500 -1.1%, $262.37 → $258.66 on Oct 1

Why it stands out

Johnson & Johnson's WWC. Innovative Medicine sold $3.95M of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 17, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 18, 2026

Officer$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$3,950,400

Shares × reported transaction price

Timing vs results

33 days after results of Jul 15, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $262.37 on Aug 17, 2026, within 2% of its 52-week high, after a 1% rise over the previous 30 trading days

52-week range $174.16 (Sep 18, 2025) to $267.24 (Jul 7, 2026), 95% of the way up, from 251 adjusted closes. 30 trading days earlier: $259.33 on Jul 6, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Imaavy on Aug 24, 2026, 7 days after this trade.

New use approved (efficacy supplement). Active ingredient: Nipocalimab-Aahu. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-1.3%	-0.4%	-0.9%
30 days	-1.3%	-1.0%	-0.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0000200406-26-000175
Filed / recorded: Aug 18, 2026, 10:31 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: JOHNSON & JOHNSON
Issuer CIK: 200406
Ticker: JNJ
Reporting person: Jennifer L Taubert
Relationship: Officer
Officer title: EVP, WWC. Innovative Medicine
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 17, 2026
Transaction code: S
Shares / units: 15,000
Price per share: $263.36
Acquired / disposed: Disposed (D)
Shares owned after: 194,451.001
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.